Medeze Group

Medeze Group OCF Margin

The Operating Cash Flow Margin of Medeze Group (MEDEZE.BK) as of Oct 27, 2026 is 22.49 %. In the previous year, Operating Cash Flow Margin was 39.42 % — a change of -42.95% (lower).

OCF Margin

22.49 %

YoY

-42.95%

Last updated:

Operating Cash Flow Margin of Medeze Group is 2025 22.49 % . Operating Cash Flow Margin of Medeze Group was 2024 39.42 % . It decreases by -42.95% lower compared to the previous year.

The Medeze Group OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
95.26 THB
Jan 1, 2019
75.15 THB
Jan 1, 2020
50.06 THB
Jan 1, 2021
36.34 THB
Jan 1, 2022
52.73 THB
Jan 1, 2023
49.57 THB
Jan 1, 2024
39.42 THB
Jan 1, 2025
22.49 THB
The Medeze Group OCF Margin history
YEAROCF MarginYoY
22.49 %-42.95%
39.42 %-20.49%
49.57 %-6.00%
52.73 %+45.13%
36.34 %-27.41%
50.06 %-33.39%
75.15 %-21.11%
95.26 %-23.93%
125.22 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medeze Group Stock analysis

What does Medeze Group do? Medeze Group PLC operates as a mesenchymal stem cell bank in Thailand, offering stem cell storage services from umbilical cord tissue and adipose tissue, alongside umbilical cord blood storage. The company provides stem cell analysis, separation, cultivation, and storage services, including immune cell potential testing for Natural killer cells. Its white blood cell potential testing service segment evaluates NK cell performance and count, while the other services segment delivers research, data collection on human cellular activities, and medical laboratory tests. The sales of products segment generates revenue through dietary supplements, cosmetics, and dermo cosmetics. The company's primary customers are individuals seeking stem cell storage for future medical use, as well as those requiring immune cell testing and research services. The stem cell sample collection service segment targets expectant parents and medical institutions for cord blood and tissue storage. The white blood cell potential testing service segment serves healthcare providers and patients interested in NK cell analysis. The sales of products segment appeals to consumers purchasing dietary supplements and cosmetic products. Medeze Group PLC's revenue streams are derived from multiple segments: stem cell storage services, immune cell testing, research and laboratory services, and product sales. The stem cell sample collection and storage services form the core offering, while the white blood cell potential testing and other services provide additional value. Product sales contribute to revenue through the distribution of dietary supplements, cosmetics, and dermo cosmetics, targeting both individual consumers and healthcare-focused markets. Medeze Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medeze Group stock

Operating Cash Flow Margin of Medeze Group is 22.49 % in 2025.

Operating Cash Flow Margin of Medeze Group changed from 39.42 % to 22.49 %, representing a -42.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Medeze Group since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Medeze Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Medeze Group

All Key Metrics — Medeze Group